ABEONA THERAPEUTICS INC. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
ABEONA THERAPEUTICS INC. (ABEO) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $8.52 million as of 2019-06-30, per its 10-Q filed 2019-08-09.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2019-08-09
- 2019-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $8.52M.
- 2019-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $8.75M.
- 2018-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2019-06-30 | $8.52M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $8.75M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $0.00 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |